Zoetis Inc. (ZTS)
Health Care3 articles
Price chart
Zoetis Inc. (ZTS) overview
Zoetis is the world’s largest animal-health company. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Zoetis Inc. trades on the NYSE under the ticker symbol ZTS. As of the most recent market data, the stock was priced around $76.56, down 0.46% on the session.
Over the past 52 weeks, ZTS has traded between $71.47 and $160.48. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 12.6, a common gauge of how richly the market prices the company's earnings. Zoetis Inc. also pays a dividend, currently yielding around 2.77%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ZTS
As one of the larger companies in the Health Care sector, Zoetis Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch ZTS for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest ZTS news
Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
Michael McCallister, a director at Zoetis (ZTS), purchased shares totaling $233,273. This stock buy may signal McCallister's confidence in the company’s future prospects. Such insider buying can influence market perceptions and potentially affect stock prices as investors interpret it as positive sentiment regarding the company's trajectory. Monitoring these insider trades can provide insights into the firm's growth potential and market strategy.
Read More: Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
Zoetis Inc (ZTS) filed its DEF 14A with the SEC for the upcoming shareholder meeting on April 30. This filing includes details on executive compensation and proposed changes to governance. Such disclosures are vital for investors assessing company management and expected performance. The filing may influence shareholder voting on key issues affecting the business.
Read More: Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally
In Q3 2024, Zoetis (ZTS) reported a 14% operational revenue growth, driven by a 15% increase in the U.S. and a 13% increase internationally. Adjusted net income saw a 15% operational rise, with key franchises, including the companion animal portfolio, also growing by 15%. The osteoarthritis pain franchise, consisting of Librela and Solensia, delivered a significant 97% operational revenue increase globally. This consistent growth reflects demand for their diverse and science-driven portfolio, positioned to address customer needs effectively.
Read More: Zoetis (ZTS) Q3 2024 Revenue Grows 14% OperationallyMore Health Care stocks
Frequently asked questions
Is Zoetis Inc. in the S&P 500?
Yes. Zoetis Inc. (ZTS) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is ZTS in?
Zoetis Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest ZTS news?
This page collects recent Zoetis Inc. (ZTS) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Zoetis Inc.'s stock price?
As of the most recent market data, Zoetis Inc. (ZTS) traded at approximately $76.56. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is ZTS's P/E ratio?
ZTS trades at a trailing price-to-earnings ratio of about 12.6. The P/E ratio compares a company's share price to its earnings per share.